THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Naoko Takebe to Female

This is a "connection" page, showing publications Naoko Takebe has written about Female.
Connection Strength

1.100
  1. Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials. Lancet. 2022 08 13; 400(10351):512-521.
    View in: PubMed
    Score: 0.064
  2. Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors. Clin Cancer Res. 2021 07 15; 27(14):3834-3844.
    View in: PubMed
    Score: 0.058
  3. A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction. Br J Clin Pharmacol. 2019 11; 85(11):2499-2511.
    View in: PubMed
    Score: 0.052
  4. Identification of high-risk drugs related to chemotherapy-induced peripheral neuropathy?in Cancer Therapy Evaluation Program-sponsored phase I trials. Eur J Cancer. 2019 07; 115:111-119.
    View in: PubMed
    Score: 0.051
  5. A Comparative Study of Longitudinal Toxicities of Cytotoxic Drugs, Molecularly Targeted Agents, Immunomodulatory Drugs, and Cancer Vaccines. Clin Pharmacol Ther. 2019 10; 106(4):803-809.
    View in: PubMed
    Score: 0.051
  6. Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose-finding trials. Cancer Sci. 2018 Jan; 109(1):207-214.
    View in: PubMed
    Score: 0.046
  7. Drug induced interstitial lung disease in oncology phase?I trials. Cancer Sci. 2016 Dec; 107(12):1830-1836.
    View in: PubMed
    Score: 0.043
  8. Analysis of esophagogastric cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase 1 trials. Gastric Cancer. 2017 May; 20(3):481-488.
    View in: PubMed
    Score: 0.042
  9. Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition. Breast Cancer Res. 2011 Jun 10; 13(3):211.
    View in: PubMed
    Score: 0.029
  10. Preliminary findings on the use of pulsatile machine reperfusion of a placenta to improve the cord blood collection yield including primitive hematopoietic stem cell fractions. Transfusion. 2009 Sep; 49(9):1911-6.
    View in: PubMed
    Score: 0.025
  11. Multiple myeloma presenting initially as a solitary pleural effusion later complicated by malignant plasmacytic ascites. Leuk Res. 2005 Jun; 29(6):715-8.
    View in: PubMed
    Score: 0.019
  12. A phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1/2 inhibitor, vistusertib, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2025 Feb 25; 95(1):37.
    View in: PubMed
    Score: 0.019
  13. Phase II Study of Defactinib (VS6063) in Patients With Tumors With NF2 Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U. JCO Precis Oncol. 2024 Dec; 8:e2400327.
    View in: PubMed
    Score: 0.019
  14. Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients. Clin Cancer Res. 2004 Dec 15; 10(24):8301-8.
    View in: PubMed
    Score: 0.019
  15. Phase II Study of Samotolisib in Children and Young Adults With Tumors Harboring Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Pathway Alterations: Pediatric MATCH APEC1621D. JCO Precis Oncol. 2024 Sep; 8:e2400258.
    View in: PubMed
    Score: 0.018
  16. Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice Trial Arm I (APEC1621I). JCO Precis Oncol. 2024 Sep; 8:e2400418.
    View in: PubMed
    Score: 0.018
  17. Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G. Oncologist. 2024 Aug 05; 29(8):723-e1093.
    View in: PubMed
    Score: 0.018
  18. Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT. Clin Cancer Res. 2024 Aug 01; 30(15):3167-3178.
    View in: PubMed
    Score: 0.018
  19. Acetalax (Oxyphenisatin Acetate, NSC 59687) and Bisacodyl Cause Oncosis in Triple-Negative Breast Cancer Cell Lines by Poisoning the Ion Exchange Membrane Protein TRPM4. Cancer Res Commun. 2024 08 01; 4(8):2101-2111.
    View in: PubMed
    Score: 0.018
  20. Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial. Oncologist. 2024 Jul 05; 29(7):638-e952.
    View in: PubMed
    Score: 0.018
  21. A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). Cancer Res Commun. 2024 07 01; 4(7):1793-1801.
    View in: PubMed
    Score: 0.018
  22. Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. JCO Precis Oncol. 2024 Jun; 8:e2400103.
    View in: PubMed
    Score: 0.018
  23. Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors. Clin Cancer Res. 2024 May 01; 30(9):1739-1749.
    View in: PubMed
    Score: 0.018
  24. The effect of liver dysfunction on the pharmacokinetic disposition of belinostat and its five metabolites in patients with advanced cancers. Cancer Chemother Pharmacol. 2024 Aug; 94(2):157-167.
    View in: PubMed
    Score: 0.018
  25. Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification. J Clin Oncol. 2023 03 20; 41(9):1725-1734.
    View in: PubMed
    Score: 0.016
  26. The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study. J Natl Cancer Inst. 2021 01 04; 113(1):27-37.
    View in: PubMed
    Score: 0.014
  27. Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903). Clin Cancer Res. 2021 03 15; 27(6):1604-1611.
    View in: PubMed
    Score: 0.014
  28. Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment. Cancer Cell. 2021 01 11; 39(1):38-53.e7.
    View in: PubMed
    Score: 0.014
  29. Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). J Clin Oncol. 2020 11 20; 38(33):3883-3894.
    View in: PubMed
    Score: 0.014
  30. The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. J Natl Cancer Inst. 2020 10 01; 112(10):1021-1029.
    View in: PubMed
    Score: 0.014
  31. A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumors. Invest New Drugs. 2020 06; 38(3):855-865.
    View in: PubMed
    Score: 0.013
  32. Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells. PLoS One. 2018; 13(6):e0199361.
    View in: PubMed
    Score: 0.012
  33. Phase I/II trial of the type I soluble recombinant human interleukin-1 receptor in HIV-1-infected patients. J Interferon Cytokine Res. 1998 May; 18(5):321-6.
    View in: PubMed
    Score: 0.012
  34. Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results : A phase I clinical trial. Invest New Drugs. 2018 06; 36(3):442-450.
    View in: PubMed
    Score: 0.011
  35. Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab. Clin Cancer Res. 2017 Jun 15; 23(12):2972-2980.
    View in: PubMed
    Score: 0.011
  36. Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508). Cancer. 2016 Aug 01; 122(15):2371-8.
    View in: PubMed
    Score: 0.010
  37. Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial. Clin Cancer Res. 2016 Oct 01; 22(19):4786-4796.
    View in: PubMed
    Score: 0.010
  38. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. Ann Oncol. 2016 Feb; 27(2):318-23.
    View in: PubMed
    Score: 0.010
  39. Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer. Cancer. 2016 Feb 15; 122(4):588-597.
    View in: PubMed
    Score: 0.010
  40. Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. J Clin Oncol. 2015 Dec 20; 33(36):4284-92.
    View in: PubMed
    Score: 0.010
  41. Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use. Clin Cancer Res. 2016 Feb 15; 22(4):1000-10.
    View in: PubMed
    Score: 0.010
  42. Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. J Clin Oncol. 2015 Aug 20; 33(24):2646-54.
    View in: PubMed
    Score: 0.010
  43. Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia. Leuk Lymphoma. 2015; 56(12):3336-42.
    View in: PubMed
    Score: 0.010
  44. Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2015 Jun; 21(6):1083-90.
    View in: PubMed
    Score: 0.010
  45. Notch1 phenotype and clinical stage progression in non-small cell lung cancer. J Hematol Oncol. 2015 Feb 06; 8:9.
    View in: PubMed
    Score: 0.009
  46. Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma. Clin Cancer Res. 2014 Dec 01; 20(23):5937-5945.
    View in: PubMed
    Score: 0.009
  47. Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1(+) leukemia. Am J Hematol. 2014 Sep; 89(9):896-903.
    View in: PubMed
    Score: 0.009
  48. GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study. Ann Oncol. 2013 Nov; 24(11):2922-6.
    View in: PubMed
    Score: 0.009
  49. Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study. Clin Cancer Res. 2013 Nov 15; 19(22):6305-12.
    View in: PubMed
    Score: 0.009
  50. A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer. Invest New Drugs. 2014 Apr; 32(2):295-302.
    View in: PubMed
    Score: 0.008
  51. Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients. Clin Cancer Res. 2013 Jun 01; 19(11):3059-67.
    View in: PubMed
    Score: 0.008
  52. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011 Jun 08; 305(22):2327-34.
    View in: PubMed
    Score: 0.007
  53. A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer. 2011 Dec; 74(3):481-5.
    View in: PubMed
    Score: 0.007
  54. Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. Cancer. 2011 May 15; 117(10):2112-9.
    View in: PubMed
    Score: 0.007
  55. Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010 Oct 20; 28(30):4609-15.
    View in: PubMed
    Score: 0.007
  56. A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer Chemother Pharmacol. 2010 Nov; 66(6):1079-85.
    View in: PubMed
    Score: 0.007
  57. NIH and NCI support for development of novel therapeutics in gynecologic cancer: a user's guide. Gynecol Oncol. 2010 Feb; 116(2):177-80.
    View in: PubMed
    Score: 0.007
  58. Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies. Leuk Res. 2007 Sep; 31(9):1165-73.
    View in: PubMed
    Score: 0.005
  59. Autologous stem cell transplantation followed by consolidation chemotherapy for patients with multiple myeloma. Bone Marrow Transplant. 2006 Jan; 37(1):65-72.
    View in: PubMed
    Score: 0.005
  60. Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients. J Clin Oncol. 2005 Jun 20; 23(18):4089-99.
    View in: PubMed
    Score: 0.005
  61. Autologous stem cell transplantation followed by consolidation chemotherapy for relapsed or refractory Hodgkin's lymphoma. Bone Marrow Transplant. 2004 Nov; 34(10):883-90.
    View in: PubMed
    Score: 0.005
  62. High-dose cyclophosphamide with or without etoposide for mobilization of peripheral blood progenitor cells in patients with multiple myeloma: efficacy and toxicity. Bone Marrow Transplant. 2004 Jul; 34(1):69-76.
    View in: PubMed
    Score: 0.005
  63. Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study. Biol Blood Marrow Transplant. 2004 Jul; 10(7):473-83.
    View in: PubMed
    Score: 0.005
  64. Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma. Bone Marrow Transplant. 2004 Apr; 33(8):781-7.
    View in: PubMed
    Score: 0.004
  65. Quantitative O(6)-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome. Clin Cancer Res. 2003 Jan; 9(1):223-7.
    View in: PubMed
    Score: 0.004
  66. Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy. Bone Marrow Transplant. 2002 Feb; 29(4):303-12.
    View in: PubMed
    Score: 0.004
  67. Gene therapy for endometrial carcinoma with the herpes simplex thymidine kinase gene. Gynecol Oncol. 2000 Mar; 76(3):305-10.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES